Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.

[1]  E. Van Cutsem,et al.  Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers , 2022, JCO precision oncology.

[2]  R. Govindan,et al.  Sotorasib for Lung Cancers with KRAS p.G12C Mutation. , 2021, The New England journal of medicine.

[3]  S. Aggarwal,et al.  A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease. , 2021, Lung cancer.

[4]  C. Langer,et al.  Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. , 2021, JAMA oncology.

[5]  P. Jänne,et al.  99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation , 2021 .

[6]  A. Warth,et al.  Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the ETOP Lungscape Project. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  W. Weichert,et al.  KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). , 2021, Lung cancer.

[8]  T. Blum,et al.  KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma , 2021, Translational lung cancer research.

[9]  T. Brummer,et al.  Immune modulatory effects of oncogenic KRAS in cancer , 2020, Nature Communications.

[10]  T. Burns,et al.  Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Novello,et al.  KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges. , 2020, European journal of cancer.

[12]  W. John,et al.  KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis. , 2020, Cancer treatment and research communications.

[13]  M. Socinski,et al.  Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma. , 2020, Clinical lung cancer.

[14]  Maarten J. IJzerman,et al.  Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. , 2020, Lung cancer.

[15]  F. McCormick,et al.  RAS-targeted therapies: is the undruggable drugged? , 2020, Nature Reviews Drug Discovery.

[16]  J. Mazières,et al.  Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes , 2020, JTO clinical and research reports.

[17]  Wei-Wei Pan,et al.  A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations , 2019, Translational oncology.

[18]  J. Fernandez-Banet,et al.  Abstract LB-C09: The KRASG12Cinhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model , 2019 .

[19]  J. Lunceford,et al.  LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042 , 2019 .

[20]  Asher Mullard.  Cracking KRAS , 2019, Nature Reviews Drug Discovery.

[21]  J. Heymach,et al.  Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy , 2019, Nature Reviews Cancer.

[22]  J. Mazières,et al.  Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[24]  K. Darwiche,et al.  Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer , 2018, Oncogene.

[25]  F. Cappuzzo,et al.  Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations , 2018, British Journal of Cancer.

[26]  M. Ladanyi,et al.  Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[27]  Frank McCormick,et al.  RAS Proteins and Their Regulators in Human Disease , 2017, Cell.

[28]  Dong-Wan Kim,et al.  KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer , 2017, The Korean journal of internal medicine.

[29]  B. Taylor,et al.  Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. , 2017, Cancer discovery.

[30]  Jian Su,et al.  Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma , 2016, Clinical Cancer Research.

[31]  C. Marquette,et al.  Impact of Kras mutant subtypes on PD-L1 expression in lung adenocarcinoma , 2016 .

[32]  P. Jänne,et al.  Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma , 2015, Clinical Cancer Research.

[33]  D. Beer,et al.  KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  H. Ji,et al.  Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[36]  C. Cole,et al.  COSMIC: the catalogue of somatic mutations in cancer , 2011, Genome Biology.

[37]  Alfred Wittinghofer,et al.  GEFs and GAPs: Critical Elements in the Control of Small G Proteins , 2007, Cell.

[38]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.